Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.30
-0.30 (-1.39%)
At close: Dec 26, 2025, 4:00 PM EST
21.15
-0.15 (-0.71%)
After-hours: Dec 26, 2025, 7:16 PM EST
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Syndax Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $36.92, which forecasts a 73.33% increase in the stock price over the next year. The lowest target is $17 and the highest is $56.
Price Target: $36.92 (+73.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 8 | 9 | 8 | 8 |
| Buy | 2 | 2 | 1 | 1 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +162.91% | Dec 9, 2025 |
| Barclays | Barclays | Buy Maintains $22 → $35 | Buy | Maintains | $22 → $35 | +64.32% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +54.93% | Nov 12, 2025 |
| UBS | UBS | Strong Buy Maintains $35 → $38 | Strong Buy | Maintains | $35 → $38 | +78.40% | Nov 4, 2025 |
| Barclays | Barclays | Buy Maintains $19 → $22 | Buy | Maintains | $19 → $22 | +3.29% | Nov 4, 2025 |
Financial Forecast
Revenue This Year
170.53M
from 23.68M
Increased by 620.14%
Revenue Next Year
367.36M
from 170.53M
Increased by 115.42%
EPS This Year
-3.18
from -3.72
EPS Next Year
-1.73
from -3.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 189.5M | 475.6M | ||||
| Avg | 170.5M | 367.4M | ||||
| Low | 155.9M | 231.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 700.4% | 178.9% | ||||
| Avg | 620.1% | 115.4% | ||||
| Low | 558.4% | 35.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.78 | -0.55 | ||||
| Avg | -3.18 | -1.73 | ||||
| Low | -3.35 | -2.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.